Safety of Intravenous Milrinone for the Treatment of Subarachnoid Hemorrhage-induced Vasospasm
Safety of Intravenous Milrinone for the Treatment of Subarachnoid Hemorrhage-induced Vasospasm
The aim of this study is to evaluate the tolerance of intravenous milrinone combined to the
 current standard treatment for cerebral vasospasm following subarachnoid hemorrhage.
 Assessment of IV milrinone safety in this setting is mandatory before the conduction of a
 large study assessing its effectiveness.
The aim of this prospective observational study is to evaluate the hemodynamic tolerance of
 intravenous milrinone for the treatment of arterial vasospasm following subarachnoid
 hemorrhage. Intravenous milrinone is part of our standard care protocol for the management of
 cerebral vasospasm in association with nimodipine (intravenous or enteral route) and high
 arterial blood pressure (mean arterial pressure of 100-120 mmHg, spontaneously or induced by
 volume expansion and norepinephrine). All patients of our ICU who were diagnosed with
 cerebral arterial vasospasm during the few days following a subarachnoid hemorrhage will be
 included.
Inclusion Criteria:

 -  Subjects 18 years

 -  Hospitalized in our intensive care unit

 -  Subarachnoid hemorrhage proven on CT angiogram

 -  Cerebral vasospasm proven on CT angiogram

 Exclusion Criteria:

 -  Pregnant women

 -  Minor

 -  Major under guardianship